Public Companies
Reunion Neuroscience Inc. to Participate in Upcoming Investor Conferences in December
Reunion Neuroscience Inc. (NASDAQ: REUN | TSX: REUN), a biopharmaceutical company committed to developing innovative and patented therapeutic solutions…
Reunion Neuroscience Inc. (NASDAQ: REUN | TSX: REUN), a biopharmaceutical company committed to developing innovative and patented therapeutic solutions for underserved mental health conditions, today announced it will be participating in the following investor conferences in December 2022.
Stifel Canada’s The Future of Healthcare Conference
Date: Wednesday, December 7, 2022
Time: 2:00 p.m. ET
Format: Presentation
Webcast: bit.ly/3AT6tFb
Canaccord Genuity Symposium on New Paradigms and Treatment Approaches in Mental Health
Date: Tuesday, December 13, 2022
Time: 10:00 a.m. ET
Format: Virtual panel ‘Opportunities/Challenges in Changing the Status Quo on Mental Health Therapeutics’
Registration: Please contact your Canaccord Genuity representative to register
KCSA Mental Health Conference
Date: Thursday, December 15, 2022
Time: 10:00 a.m. ET
Format: Virtual presentation
Webcast: https://bit.ly/3Ub0iE3
Recordings of the webcast presentations will be available on the Events and Presentations section of Reunion’s investor relations website following the events.
The Reunion management team will also participate in one-on-one investor meetings during the conferences. For institutional investors to schedule a meeting, please contact reunion@kcsa.com.
About Reunion Neuroscience Inc
Reunion (formerly, Field Trip Health Ltd.) is committed to developing innovative therapeutic solutions for mental health conditions. The Company’s lead asset, RE104, is a proprietary, novel serotonergic psychedelic compound being developed as a potential fast-acting and durable antidepressant for patients suffering from postpartum depression and other mental health conditions. The U.S. Patent and Trademark Office has granted the Company a patent for the claims related to RE104, granting it exclusive rights to the composition of matter, use and manufacturing of a family of hemi-ester compounds of hydroxytryptamines, including RE104. The patent will provide protection until 2041. Reunion is also developing the RE200 series, which includes compounds with potential for more selective serotonin receptor activity with reduced psychoactivity for potential use in more chronic treatment paradigms and indications.
-
Psilocybin1 week ago
Psychedelic Underground Celebrated in San Francisco on Bicycle Day Weekend
-
Psychedelics7 days ago
Freedom Biosciences Announces FDA Approval of IND Application for FREE001 in Patients with Treatment-Resistant Depression
-
Law & Regulation6 days ago
Compass Pathways, Journey Clinical to develop psilocybin treatment delivery model
-
Psychedelics1 week ago
Compass Pathways and Journey Clinical Establish Research Collaboration Agreement To Inform the Training of Healthcare Providers and Delivery Model for COMP360 Psilocybin Treatment, If Approved for Treatment-Resistant Depression
-
Psychedelics1 week ago
Cybin to Participate at the 27th Annual Milken Institute Global Conference
-
Ketamine7 days ago
DEA poised to move cannabis to Schedule III
-
Psychedelics5 days ago
Reunion Neuroscience Inc. Announces $103 Million Series A Financing Co-Led by MPM BioImpact and Novo Holdings
-
Psychedelics7 days ago
Behold! A New Mushroom Emoji Has Arrived!